Are you Dr. Kaufmann?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 51 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
5 Skinner St
Port Jervis, NY 12771Phone+1 845-858-2666Fax+1 845-858-2662- Is this information wrong?
Summary
- Dr. Walter Kaufmann, MD is a cardiologist in Port Jervis, New York. He is currently licensed to practice medicine in New York and New Jersey. He is affiliated with Bon Secours Community Hospital.
Education & Training
- Newark Beth Israel Medical CenterFellowship, Cardiovascular Disease, 1980 - 1982
- Rutgers Health/New Jersey Medical SchoolResidency, Internal Medicine, 1977 - 1980
- Rutgers New Jersey Medical SchoolClass of 1977
Certifications & Licensure
- NJ State Medical License Current
- NY State Medical License 1982 - 2026
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
- Fellow (FACC) American College of Cardiology
Publications & Presentations
PubMed
- Autism Spectrum Disorder in Fragile X Syndrome: Cooccurring Conditions and Current TreatmentAmy Esler, Stephanie L Sherman, Dejan B Budimirovic, Tracy Stackhouse, Walter E Kaufmann, Georgina Peacock> ;AAP News. 2017 Aug 18
- [Cardiovascular risk factors in adolescents. 1st results of the Cologne-study 1975/76].Laaser, U., Schütt, A., Kuschinsky, Gisela, Perbix, W., Meurer, K. A., Kaufmann, W.> ;Verh Dtsch Ges Inn Med. 1976
- [The spread of nicotine abuse in students; a partial account of the study in Cologne on the risk profile in adolescents].Laaser, U., Roegele, F., Meurer, K. A., Kaufmann, W.> ;Verh Dtsch Ges Inn Med. 1977 Apr 17
- Join now to see all
Press Mentions
- Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (Blarcamesine) in Rett SyndromeNovember 6th, 2019
- Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from the U.S. Rett Syndrome Phase 2 ANAVEX®2-73 StudySeptember 27th, 2019
- Anavex Life Sciences Reports Fiscal 2019 First Quarter Financial Results and Provides Clinical Study UpdatesMarch 28th, 2019
Professional Memberships
- Member
Hospital Affiliations
- Bon Secours Community HospitalPort Jervis, New York